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ABSTRACT
Background. The phase II YO28252 study (NCT01590719)
examined first-line onartuzumab plus mFOLFOX6 in patients
with metastatic, human epidermal growth factor receptor
2-negative adenocarcinoma of the stomach or gastroesoph-
ageal junction. MET immunohistochemistry expression as a
biomarker of onartuzumab activity was also examined.
Patients and Methods. Patients were randomized 1:1 to receive
standard mFOLFOX6 plus onartuzumab (10 mg/kg) or placebo in
2-weekcyclesfor12cycles,followedbyonartuzumaborplacebountil
disease progression. Coprimary endpoints were progression-free
survival (PFS) in intent-to-treat (ITT) andMET-positive populations.
The target hazard ratio (HR) was 0.70 for patients in the ITT group
and0.60intheMET-positivepopulation.Secondaryendpointswere
overall survival (OS), overall response rate (ORR), and safety.
Results. Overall,123patientswereenrolled (n562onartuzumab,
n 5 61 placebo). Median PFS was 6.77 versus 6.97 months for
onartuzumab versus placebo, respectively (HR, 1.08; 95% confi-
dence interval [CI], 0.71–1.63; p 5 .71). In the MET-positive
population,medianPFSwas5.95versus6.80months,onartuzumab
versus placebo (HR, 1.38; 95% CI, 0.60–3.20; p5 .45). Median OS
was 10.61 months for onartuzumab versus 11.27 months for
placebo) (HR, 1.06, 0.64–1.75; p 5 .83). In the MET-positive
population, median OS was 8.51 versus 8.48 months for
onartuzumab versus placebo, respectively (HR, 1.12, 95% CI,
0.45–2.78; p5 .80). ORR was 60.5% for the onartuzumab group
and57.1%forplacebo.Grade3–5adverseevents(AEs)wereseenin
88.3% of patients receiving onartuzumab and in 78.3% of patients
receiving placebo, with serious AEs in 55% and 40%, respectively.
Conclusion.TheadditionofonartuzumabtomFOLFOX6ingastric
cancerdidnot improveefficacy inanunselectedpopulationor ina
MET immunohistochemistry-positivepopulation.TheOncologist
2016;21:1085–1090
Implications for Practice: The YO28252 study demonstrated that the addition of the anti-MET agent onartuzumab tomFOLFOX6
for treatment of gastric cancer did not improve efficacy in an overall study population or those selected for positiveMETstatus by
immunohistochemistry. This highlights the importance of correctly selecting biomarkers for targeted therapies. A multivariate
analysis suggested that MET positivity may still be prognostic for worse median overall survival in gastric cancer; therefore, it is
important to continue investigation into the optimal approach to inhibit MET signaling in gastric cancer.
INTRODUCTION
Adenocarcinomas of the stomach and gastroesophageal
junction (GEJ) have a highmortality rate, with approximately 1
million cases per year [1]. The current standards of care for
advanced gastric cancer include first-line platinum- and
fluoropyrimidine-based regimens such as capecitabine/
cisplatinor leucovorin/fluorouracil (5-FU)/oxaliplatin (FOLFOX),
taxane-based regimens such as docetaxel/5-FU/cisplatin, and
irinotecan-based regimens. For gastric cancer overexpressing
human epidermal growth factor-2 (HER2), trastuzumab
plus chemotherapy is the current standard treatment [2, 3].
Despite these options, prognosis for advanced gastric cancer is
still poor, with median overall survival (OS) of approximately
8–11 months [4]; therefore, there is an urgent need for new
therapies.
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The MET pathway represents a potential new target in
oncology.SignalingthroughtheMETpathwaystimulatestissue
repair and regeneration in normal tissue but can promote
proliferation, survival, andmetastasis inmalignancies [5].MET
is expressed in a number of cancers, with METoverexpression
as assessed by immunohistochemistry (IHC) shown in gastric
cancer by Ha et al. [6]. Aberrant upregulation of the MET/
hepatocyte growth factor (HGF) pathway is associated with
poor prognosis in multiple malignancies, including gastric
cancer [7], with MET overexpression by IHC being associated
with poor survival in several studies [8]. In a study byNakajima
et al. [9], METoverexpression by IHC in gastric cancer patients
was correlated with depth of tumor invasion, lymph node
metastases, and poorer survival rates (all p, .001).
Onartuzumab is a fully humanized, monovalent, anti-MET
antibody that inhibits HGF binding and receptor activation.
Preliminary data from phase I/II studies indicated that MET-
targeted agents, including rilotumumab and onartuzumab, are
active in gastric cancer [10, 11]. In aphase I studyofonartuzumab,
onepatientwithgastric cancerwithMEToverexpressionachieved
complete radiographic response after four cycles of mono-
therapy [10].Theanti-METagent rilotumumabreportedmedian
progression-free survival (PFS) of 5.7months versus 4.2months
for placebo in a phase II trial [11]. Gastric cancer with MET
amplification has also been shown to be responsive to the ALK/
ROS/MET inhibitor crizotinib [12].Together, thesedataprovided
evidence thatMET is a potentially important target in advanced
gastriccancer,andthatonartuzumabmaybeasuitabletreatment for
tumorswithaberrantsignalingof theMETpathway.Therefore,the
phase II YO28252 study (NCT01590719; www.clinicaltrials.gov)
was initiated to examine the efficacy and safety of onartuzumab
in combination with mFOLFOX6 as first-line treatment for
metastatic,HER2-negativegastric cancer.MET IHCexpressionas
a biomarker of onartuzumab activity was also examined.
PATIENTS AND METHODS
Study Design
YO28252 was a randomized, phase II, multicenter, double-blind,
placebo-controlled study evaluating the safety and efficacy of
onartuzumab plus mFOLFOX6 compared with placebo plus
mFOLFOX6 in patients with histologically confirmed, meta-
static HER2-negative gastric cancer thatwas not amenable to
curative therapy.YO28252 was conducted in more than 30 sites
across Australia, Korea, Singapore, Taiwan, Thailand, and the
U.S. Eligible patients were randomized 1:1 by an interactive
voice response system to receive onartuzumab (10 mg/kg) plus
mFOLFOX6 (400 mg/m2 bolus and 2,400 mg/m2 intravenous
5-FU for 46–48 hours, 200 mg/m2 leucovorin, and 85 mg/m2
oxaliplatin for 2 hours) or placebo plus mFOLFOX6 in 2-week
cycles for 12 cycles, followedbyonartuzumaborplacebountil
disease progression. Patients were stratified by Lauren
histologic subtype and prior gastrectomy.
Patients
Inclusion criteria were as follows: age $18 years with Eastern
CooperativeOncologyGroupperformance status (ECOGPS) 0 or 1,
with histologically confirmed, inoperable, metastatic adenocarci-
noma of the stomach or GEJ. Tissue samples from the primary
tumor site or metastatic sites were required for central MET and
HER2 status assessment. Exclusion criteria includedHER2-positive
disease,previouschemotherapyfor locallyadvancedormetastatic
disease, or therapy targeting theMETpathway. Further exclusion
criteria are detailed in the supplemental online Appendix.
Objectives
The coprimary endpoints were PFS in the intent-to-treat (ITT)
populationand intheMET-positivepopulation(definedasthose
with $50% of tumor cells with moderate or strong intensity
staining) using MET IHC scoring based on a 50% staining
algorithm using the Ventana CONFIRM anti-total c-MET (SP44)
IHC assay (supplemental online Fig. 1). We also examined an
exploratorycutoff forMETpositivityof.90%tumorcell staining
[13]. Secondary endpoints included OS (in the ITT and MET-
positive populations), overall response rate (ORR), and safety.
Exploratorybiomarkeranalysis investigatedHGFtumor levelsas
a potential biomarker for efficacy outcomes.
The studywas conducted in accordancewith the principles
of the Declaration of Helsinki and Good Clinical Practice and
received the appropriate ethics or independent review board
approval. Patients provided written informed consent to
participate in the study.
Statistical Analysis
With a planned sample size of 120 patients and data cutoff
after 84 PFS events observed, the target hazard ratios (HRs)
were 0.70 in the ITT population and 0.60 in the MET-positive
Table1. Baselinecharacteristics inthe intent-to-treatpopulation
Characteristics
Onartuzumab1
mFOLFOX6
(n5 62)a
Placebo1
mFOLFOX6
(n5 61)a
Median age, years (range) 58.5 (33–78) 57.0 (31–82)
Sex, n (%)
Male 40 (64.5) 36 (59.0)
Female 22 (35.5) 25 (41.0)
Race, n (%)
White 25 (40.3) 19 (31.1)
Black 1 (1.6) 3 (4.9)
Asian 35 (56.5) 36 (59.0)
Other 1 (1.6) 3 (4.9)
ECOG PS, n (%) n5 59 n5 60
0 24 (40.7) 24 (40.0)
1 35 (59.3) 36 (60.0)
Primary tumor site, n (%)
Stomach 46 (74.2) 48 (78.7)
Gastroesophageal junction 16 (25.8) 13 (21.3)
Lauren histologic subtype, n (%)
Intestinal 20 (32.3) 23 (37.7)
Diffuse 31 (50.0) 26 (42.6)
Mixed 9 (14.5) 11 (18.0)
Not evaluable 2 (3.2) 1 (1.6)
Prior gastrectomy, n (%)
Yes 23 (37.1) 20 (32.8)
No 39 (62.9) 41 (67.2)
aNumber for subgroups unless otherwise specified.
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group
performance status.
©AlphaMed Press 2016
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population. This trial was not planned to have adequate
power to detect minimum clinically meaningful differ-
ences between the treatment arms. Therefore, formal
hypothesis testing was limited because statistically nega-
tive outcomes do not necessarily rule out clinically
significant treatment effects. P values were two-sided.
Kaplan-Meiermethodology was used to assess PFS andOS.
Response Evaluation Criteria in Solid Tumors version 1.1
was used to evaluate tumor response every 6 weeks; ORR
(partial or complete best overall response)was assessed by
investigators. Safety was evaluated at every visit using the
NationalCancerInstituteCommonTerminologyCriteriaforAdverse
Events version 4.0.
RESULTS
Patients
Between July 25, 2012, and May 29, 2013, a total of 123
patients were enrolled and randomly assigned to treatment
(n5 62 to the onartuzumab arm; n5 61 to the placebo arm;
supplemental online Fig. 2). The ITT population comprised
all 123 patients who were randomized to treatment. Only
Figure 1. PFS study data. (A): The ITT population. (B): The MET-positive population. (C): Patient subgroups. *, 50% staining cutoff;
a, unstratified analysis.
Abbreviations: CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group Performance Status; HR, hazard ratio; ITT,
intent-to-treat group; NE, not evaluable; PFS, progression-free survival.
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patients who received at least 1 dose of study treatment
were included in the safety population (n 5 60 in each
treatment arm). Baseline characteristics are shown in
Table 1; there were no substantial differences between
the two arms. MET expression is shown in supplemental
online Table 1. Using the 50% cutoff, 28% of patients in the
onartuzumab arm and 33% of patients in the placebo arm
were included in the MET-positive population (IHC score
21 or 31).
Efficacy
Median follow-up was 9.2 months for the onartuzumab arm
and9.1months for theplaceboarm.A total of 30patients from
the onartuzumab arm and 33 patients from the placebo arm
had completed 12 cycles of treatment at the data cutoff date
of January 29, 2014, with median treatment durations of
5.6months and 6.5months, respectively.Themedian number
of cycles completed was 11.0 for onartuzumab-treated
patients and 13.5 for placebo-treated patients. Median dose
intensity was 91.0% and 94.1%, respectively, for onartuzumab
and placebo.
At the data cutoff date of January 29, 2014, themedian PFS in
the ITT population was 6.77 months in the onartuzumab arm
versus 6.97 months with placebo (stratified HR, 1.08; 95%
confidence interval [CI], 0.71–1.63; p5 .71; Fig. 1A). In the MET-
positive population (MET IHC 21, 31, 50% staining cut-off),
medianPFSwas5.95monthsversus6.80months, respectively, for
onartuzumab versus placebo (stratified HR, 1.38; 95% CI,
0.60–3.20; p5 .45; Fig. 1B). The stratified HR for PFS in the MET-
negative population (MET IHC 0 or 11, 50% staining cut-off) was
0.99 (95% CI, 0.59–1.68; p 5 .98; median PFS, 7.03 months for
onartuzumaband7.72monthsforplacebo).PFSsubgroupanalyses
were consistent with the ITTpopulation (Fig. 1C). Exploratory PFS
analysesbydifferentMET-positivedefinitions (IHC11, 21, 31 vs.
21, 31) and by different MET staining cutoffs (50% vs. 90%) are
showninsupplementalonlineFigure3.Regardlessofthedefinition
of METpositivity or staining cutoff used, median PFS was not
significantly different between the treatment arms. Multivariate
analysis forPFS showedthatECOGPS (0vs. 1,p5 .004) and tumor
location(stomachvs.GEJ,p5 .0024)wereindependentprognostic
factors for PFS (supplemental online Table 2).
At the time of the OS final analysis data cutoff, 34 patients
(54.8%)fromtheonartuzumabarmand30patients (49.2%)from
the placebo arm had died. Median OS in the ITTpopulation was
10.61months foronartuzumabversus11.27months forplacebo
(HR,1.06;95%CI,0.64–1.75;p5 .83;Fig.2A). IntheMET-positive
population, median OS was 8.51 months versus 8.48 months,
respectively, for onartuzumab and placebo (HR, 1.12; 95% CI,
0.45–2.78; p5 .80; Fig. 2B).The stratified HR for OS in theMET-
negative population was 1.09 (95% CI, 0.56–2.12; p 5 .79;
median OS, 10.91 months for onartuzumab and 13.34 months
for placebo).Multivariate analysis showedMETpositivitywas an
independent poor prognostic factor for OS, as well as ECOG PS
and prior chemotherapy (supplemental online Table 3).
The ORR in the ITT population with baseline measurable
disease was 60.5% (26 of 43; n5 4 complete responses) for
the onartuzumab arm and 57.1% (24 of 42; n 5 1 complete
response) for placebo. This resulted in a disease control rate
(ORR plus stable disease) of 81.4% and 83.3%, respectively.
HGF Biomarker Analysis
Baseline tumorHGF levels assessed by polymerase chain reaction
(PCR; 25% upper PCR levels vs. 75% lower PCR levels) did not
identify any biomarker activity for PFS or OS in the ITTpopulation
Figure 2. OS study data. (A): The ITT population. (B): The MET-positive population. *, staining cutoff.
Abbreviations: CI, confidence interval; HR, hazard ratio; ITT, intent-to-treat group; OS, overall survival.
Table2. Adverseevents reported in$25%ofeither treatment
arm (safety population)
Adverse Event
Onartuzumab1
mFOLFOX6
(n5 60), n (%)
Placebo1
mFOLFOX6
(n5 60), n (%)
Nausea 41 (68.3) 38 (63.3)
Vomiting 28 (46.7) 27 (45.0)
Diarrhea 29 (48.3) 24 (40.0)
Constipation 17 (28.3) 23 (38.3)
Abdominal pain 15 (25.0) 14 (23.3)
Peripheral neuropathy 22 (36.7) 25 (41.7)
Neutropenia 38 (63.3) 30 (50.0)
Fatigue 26 (43.3) 33 (55.0)
Peripheral edema 33 (55.0) 9 (15.0)
©AlphaMed Press 2016
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(supplementalonlineFig.4A)or insubgroupsstratifiedbyMETIHC
status, ethnicity (Asian; supplemental online Fig. 4B), or primary
tumor location (stomach; supplemental online Fig. 4C). The
Subpopulation Treatment Effect Pattern Plots show the moving
HR for different levels of HGF expression based on percentile.The
graphs suggest that levels of HGF expression were not associated
with better outcomes in any of the subgroups analyzed.
Safety
The most frequently reported ($25%) adverse events (AEs) in
both treatment arms (Table 2) included nausea (68.3% vs.
63.3%), vomiting (46.7% vs. 45.0%), and diarrhea (48.3% vs.
40.0%) for onartuzumab versus placebo, respectively. Related
AEs were reported in 100% of patients who received onartuzu-
maband93.3%ofpatientswhoreceivedplacebo.Grade3–5AEs
were seen in 88.3% and 78.3% of patients in the onartuzumab
and placebo arms, respectively, with serious AEs in 55% and
40% of patients, respectively. Grade 3–5 AEs observed more
frequently with onartuzumab than with placebo ($5% differ-
ence) included neutropenia (58% vs. 45%), thrombocytopenia
(10% vs. 3%), peripheral edema (10% vs. 0%), and pulmonary
embolism (7% vs. 2%). AEs of special interest, including edema
and thrombotic events, are shown in Table 3. Four grade 5 AEs
occurred in the onartuzumab arm (gastric perforation, septic
shock, sepsis, and hypotension); 2 occurred in the placebo arm
(congestive heart failure and cerebral hemorrhage).
DISCUSSION
AberrantupregulationoftheMETpathwayisassociatedwithpoor
prognosis in gastric cancer [9]. Onartuzumab inhibits MET
signaling byblocking ligand-dependent receptor activation. In
this multicenter, randomized study, the addition of onartuzu-
mab to first-line mFOLFOX6 for metastatic gastric cancer did not
improvePFS inthe ITTpopulation(HR,1.08)or intheMET-positive
subgroup (IHC 21, 31; HR, 1.38). Secondary endpoints of
improved OS and ORR with the addition of onartuzumab were
also not achieved.These data suggest that inhibition of the HGF/
MET pathway may be ineffective for the treatment of gastric
cancer. The RILOMET-1 phase III study of HGF inhibitor
rilotumumab for gastric cancer also reported negative results
andclosedprematurelybecauseof lackofactivity [14].Circulating
HGF levelshavebeenexplored inother tumor typesasapotential
biomarker for MET inhibitor efficacy [15], and high levels of
circulating HGF were found in the patient who had a complete
response in the phase I study [10]; however, HGF levels
determinedbyPCRhadno relationshipwith efficacy in this study.
Thissuggeststhatalternativebiomarkersareneededtodefinethe
optimal patient population for onartuzumab. The lack of further
biomarkeranalysis inYO28252maybeconsideredalimitationand
the small total numbers, particularly in the subgroup analyses,
must be taken into account when reviewing the data presented.
The safety profile of onartuzumab was as expected, with
edema,venousthromboembolism,andAEs leadingtotreatment
discontinuation being more frequent in the onartuzumab arm
than in the placebo arm. No new safety signals were observed.
Although onartuzumab is a potent, selective inhibitor of the
METsignaling pathway, its addition to standard chemotherapy for
gastric cancer did not improve efficacy in the ITTor MET-positive
populations at increasingly stringent thresholds of MET-positive
criteria. One consideration could be that the presence of
chemotherapy could cause a negative interaction with onartuzu-
mab, thereby counteracting any benefit from the addition of
onartuzumab. However, based on the data available and the lack
of efficacy of onartuzumab in other nonchemotherapy regimens,
this appears unlikely. The YO28252 data suggest that either
inhibition of METsignaling by a ligand-blocking antibody is not an
appropriate strategy in gastric cancer, perhaps due to redundant
mechanismsofpathwayactivation,orthatMETIHCdoesnotselect
Table 3. Onartuzumab-associated adverse events of special interest
Adverse Event
Onartuzumab1mFOLFOX6
(n5 60), n (%)
Placebo1mFOLFOX6
(n5 60), n (%)
Any grade Grade ‡3 Any grade Grade ‡3
Embolic and thrombotic events: arterial, overall 2 (3.3) 1 (1.7) 0 (0.0) 0 (0.0)
Acute myocardial infarction 1 (1.7) 1 (1.7) 0 (0.0) 0 (0.0)
Transient ischemic attack 1 (1.7) 0 (0.0) 0 (0.0) 0 (0.0)
Embolic and thrombotic events: venous, overall 14 (23.3) 7 (11.7) 5 (8.3) 3 (5.0)
Deep vein thrombosis 7 (11.7) 1 (1.7) 5 (8.3) 2 (3.3)
Pulmonary embolism 5 (8.3) 4 (6.7) 1 (1.7) 1 (1.7)
Other thrombosis 4 (6.7) 2 (3.3) 0 (0.0) 0 (0.0)
Gastrointestinal perforation, overall 3 (5.0) 2 (3.3) 2 (3.3) 1 (1.7)
Peritonitis bacterial 1 (1.7) 1 (1.7) 1 (1.7) 1 (1.7)
Abdominal abscess 0 (0.0) 0 (0.0) 1 (1.7) 0 (0.0)
Anal fistula 1 (1.7) 0 (0.0) 0 (0.0) 0 (0.0)
Gastric perforation 1 (1.7) 1 (1.7) 0 (0.0) 0 (0.0)
Edema, overall 37 (61.7) 6 (10.0) 10 (16.7) 2 (3.3)
Peripheral edema 33 (55.0) 6 (10.0) 9 (15.0) 0 (0.0)
Local swelling 5 (8.3) 0 (0.0) 0 (0.0) 0 (0.0)
Generalized edema/edema 6 (10) 3 (5.0) 1 (1.7) 1 (1.7)
Fluid overload 0 (0.0) 0 (0.0) 1 (1.7) 1 (1.7)
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appropriately for MET-driven tumors. The mode of action of
onartuzumabmaybeworthconsidering,asbothonartuzumaband
rilotumumab are designed to inhibit ligand-dependent activation
of MET signaling. These drugs, therefore, may be ineffective at
inhibiting signaling from receptors with activating mutations.
Adenosine triphosphate-competitive small molecules would be
expected to inhibit ligand-independent MET receptor activity
driven by mutations, as seen in promising response data from
crizotinib inMET-amplified patients [13]. However, this hypothesis
is linked with the identification of the corresponding predictive
biomarkerbecausereceptoractivationandamplificationmaypoint
to different biology and response to different anti-MET therapies.
Alternative biomarkers to guide patient selection may be
required to see thebest results for onartuzumab in gastric cancer.
One such option is MET amplification, which may be a more
appropriate biomarker to select for tumors that will respond to
MET inhibitors. Preliminary data for the MET inhibitor AMG337
showed that, in 10 patients withMET-amplified gastric cancer, 1
patient achieved a complete response and 4 had partial responses;
however, further investigations have been terminated [16].
There are a number of reasons why the promising
preclinical and phase I findings of onartuzumab perhaps did
not translate to promising phase II data in gastric cancer.These
include the increased patient population in phase II trials,
alternative oncogenic signaling pathways that may not be
blockedbyonartuzumab, and theuseof IHCas the chosenMET
biomarker. The multivariate analysis suggested that MET
positivitymaystill beprognostic forworsemedianOS in gastric
cancer; therefore, it is important to continue investigation into
the optimal approach to inhibitMETsignaling in gastric cancer.
CONCLUSION
The YO28252 study demonstrated that the addition of
onartuzumab to mFOLFOX6 in metastatic gastric cancer did
not provide a clinical benefit in either the ITT population or in
patients with MET-positive tumors as defined by MET IHC.
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